DRG Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of NSCLC for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.

DRG Epidemiology’s NSCLC forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with NSCLC per year?
  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with NSCLC per year?
  • How will improvements in survival change the number of first-line drug-treatment opportunities for NSCLC?
  • How will the declining risk of recurrence change the number of first-line drug-treatment opportunities for NSCLC?
  • Of all people diagnosed with NSCLC, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of NSCLC over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following NSCLC subpopulations:

  • Diagnosed incident cases: adenocarcinoma by ALK translocation status.
  • Diagnosed incident cases: adenocarcinoma by EGFR translocation status.
  • Diagnosed incident cases: adenocarcinoma by KRAS mutation status.
  • Diagnosed incident cases: adenocarcinoma by stage and resection status.
  • Diagnosed incident cases: NSCLC by ALK translocation status.
  • Diagnosed incident cases: NSCLC by EGFR mutation status.
  • Diagnosed incident cases: NSCLC by KRAS mutation status.
  • Diagnosed incident cases: squamous NSCLCby stage and resection status.
  • Diagnosed incident cases:NSCLCunverified by stage at diagnosis.

Note: Coverage may vary by country.

Table of contents

  • Mature Markets
    • Introduction
      • Key Findings
      • Overview
        • Incidence of Non-Small-Cell Lung Cancer per Year per 100,000 People of All Ages in 2019 and 2039
        • Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Non-Small-Cell Lung Cancer over the Next 20 Years
        • Analysis of the Incident Cases of Non-Small-Cell Lung Cancer in 2019 by Stage at Diagnosis
        • Number of Incident Cases of Non-Small-Cell Lung Cancer Avoided in the Countries Under Study During 2019-2039 due to Trends in Risk
    • Epidemiology Data
    • Methods
      • Lifetime DALYs Gained
      • Newly Diagnosed Incidence
      • Stage Distribution
      • Mutation Status
      • Recurrent Incidence
      • Diagnosed Prevalence
      • Drug-Treatable Population
      • Drug-Treated Population
    • Reference Materials
      • Literature Review
      • Risk/Protective Factors
      • Bibliography

Author(s): Atul Sharma, MPH

Atul Sharma started working in Decision Resources Group as an intern in early 2016 and currently works as an associate epidemiologist. He performs fully documented systematic reviews of both published and grey literature on the epidemiology of assigned diseases and their risk factors to estimate incidence/prevalence over a 10-30 year period. He produces analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets. He holds a Master’s in Public Health degree from School of Public Health, Post-Graduate Institute of Medical Education and Research and a Bachelor’s in dental surgery from MN DAV Dental College & Hospital.


Related Reports

Non-Small-Cell Lung Cancer | Unmet Need | Detailed, Expanded Analysis: EGFR-positive metastatic non-squamous NSCLC (US & EU)

EGFR-mutation-status determination is a mandatory step in the treatment algorithm for patients with advanced non-small-cell lung can...

View Details

Non-Small-Cell Lung Cancer | Landscape & Forecast | Disease Landscape & Forecast

Non-small-cell lung cancer (NSCLC) is one of the most dynamic oncology indications and a key area of focus for drug developers. Immune checkpoint i...

View Details

Non-Small-Cell Lung Cancer | Geographic Focus: China | Non-Small-Cell Lung Cancer | China In-Depth | China

MARKET OUTLOOK Non-small cell lung cancer (NSCLC) is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths in China. NSCLC has one of...

View Details

Non-Small-Cell Lung Cancer | Access & Reimbursement | Detailed, Expanded Analysis (EU)

MARKET OUTLOOK Non-small-cell lung cancer (NSCLC) has a high incidence and a large number of premium-priced therapies, wh...

View Details